AnserBio Ltd
General Data
Reg Number
515596310
Sector
Biomed
Established
2017
No. of Employees
8
Stage
R&D
Additional Funding
1
Description
AnserBio is developing EXOp53, a first-in-class exosome-based p53 therapy. Lead program targets HPV-driven precancerous lesions. Strong momentum towards FDA engagement, scale-up, and Series A financing
Technology
AnserBio supplies healthy p53 protein to cancer cells using natural nano-particles, called exosomes that can be delivered by multiple administration routes for cancer treatment.
Targeted Customers
Cancer patients, Pharmaceuticals industry.
Management personnel
Winning details
Route name
Winning year
Technological Incubators 2020
Technological Incubators 2020
2023